Niraparib Tosylate Monohydrate (CAS 1613220-15-7)
« Back to Anti-Cancer API
Niraparib Tosylate Monohydrate
CAS No. 1613220-15-7
甲苯磺酸尼拉帕利一水合物
Chemical structure
| CAS No. | 1613220-15-7 |
|---|---|
| Synonyms | 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide 4-methylbenzenesulfonate hydrate (1:1:1) |
| Category | Anti-Cancer API / Anti-Cancer |
| Assay / Purity | 99% |
| Molecular Formula | C26H30N4O5S |
| Molecular Weight | 510.6 |
| Melting Point | — |
| Boiling Point | — |
| Density | — |
| Flash Point | — |
| Appearance | Off-white to white solid powder |
Application and positioning
Niraparib tosylate monohydrate is the crystalline tosylate monohydrate salt of the PARP-1/2 inhibitor niraparib. It is used in oral capsules and tablets as maintenance therapy for advanced ovarian, fallopian tube and primary peritoneal cancer. Laurand supplies it from audited Chinese production partners for pharmaceutical manufacturing and process development.
Quality and documentation
- Batch-specific Certificate of Analysis issued by the manufacturing site
- SDS/MSDS and specification sheet available on request
- Residual solvents and elemental impurities statements discussed per project
- For pharmaceutical manufacturing and R&D use only — not for direct administration
Packaging and handling
- Packed in double polyethylene-lined fibre drums; pack size confirmed at quotation
- Small quantities in sealed aluminium foil bags
- Palletised for air and sea freight; store dry, ventilated and protected from light
Related products
- Osimertinib Mesylate (CAS 1421373-66-1)
- Pazopanib Hydrochloride (CAS 635702-64-6)
- Ponatinib Hydrochloride (CAS 1114544-31-8)
- Poziotinib (CAS 1092364-38-9)
Specifications shown are indicative. The final specification and documentation package are confirmed with the quotation.
Interested in this product?
Contact us for price, COA, MSDS and lead time — custom synthesis available.
Request a QuoteReference: CAS 1613220-15-7 · PubChem CID 74763937